PERRIGO Co plc
For the period ended Mar 29, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 29, 2025 · Filed May 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Revenue Recognition
NOTE 2 -REVENUE RECOGNITION
The following is a summary of our net sales by category (in millions):
| Three Months Ended | ||
|---|---|---|
| March 29, 2025 | March 30, 2024 | |
| CSCA | ||
| Upper Respiratory | $137.9 | $130.3 |
| Nutrition | 104.8 | 90.6 |
| Digestive Health | 103.0 | 122.2 |
| Pain and Sleep-Aids | 76.6 | 82.6 |
| Healthy Lifestyle | 70.4 | 71.3 |
| Oral Care | 62.0 | 64.7 |
| Skin Care | 48.6 | 49.6 |
| Women's Health | 15.0 | 27.2 |
| Vitamins, Minerals, and Supplements ("VMS") | 1.6 | 4.2 |
| Other CSCA(1) | 0.8 | 1.4 |
| Total CSCA | $620.7 | $644.1 |
| CSCI | ||
| Skin Care | $111.5 | $114.7 |
| Upper Respiratory | 73.5 | 69.1 |
| Healthy Lifestyle | 66.6 | 64.6 |
| Pain and Sleep-Aids | 53.6 | 51.4 |
| VMS | 37.7 | 44.6 |
| Women's Health | 32.4 | 32.0 |
| Oral Care | 22.5 | 28.7 |
| Digestive Health | 9.6 | 9.5 |
| Other CSCI(1) | 15.9 | 23.3 |
| Total CSCI | $423.1 | $437.9 |
| Total net sales | $1,043.9 | $1,082.1 |
(1) Consists primarily of other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.
The following table provides information about contract assets from contracts with customers (in millions):
| Balance Sheet Location | March 29, 2025 | December 31, 2024 | |
|---|---|---|---|
| Short-term contract assets | Prepaid expenses and other current assets | $38.2 | $43.9 |
Note 2
We generated net sales in the following geographic locations(1) (in millions):
| Three Months Ended | ||
|---|---|---|
| March 29, 2025 | March 30, 2024 | |
| U.S. | $609.3 | $632.3 |
| Europe(2) | 412.3 | 419.7 |
| All other countries(3) | 22.3 | 30.1 |
| Total net sales | $1,043.9 | $1,082.1 |
(1) The net sales by geography are derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $11.0 million for the three months ended March 29, 2025, and $4.3 million for the three months ended March 30, 2024.
(3) Includes net sales generated primarily in Australia and Canada.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.